Navigation Links
ChanTest Initiates Project for the US FDA to Improve Understanding of the Interaction of Tobacco Products with Human Nicotinic Receptors

Cleveland (PRWEB) August 20, 2013

ChanTest, a Contract Research Organization and world leader in ion channel drug safety and discovery, announces initiation of a project funded by the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP). CTP’s mission is to improve our understanding of the pharmacology of tobacco product substituent compounds and to enhance the regulation of tobacco products.

The FDA’s authority to regulate the manufacture, distribution, and marketing of tobacco products to protect public health stems from The Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), which became law on June 22, 2009. The FDA's funding of this ChanTest project falls under a regulatory science initiative calling for innovation in technology to convert basic science to real-world applications.

The goals of the one-year study are to develop cell lines that express human nicotinic receptor subtypes, and to optimize high-throughput testing of exploratory compounds against nicotinic receptors in automated patch clamp and fluorometric plate-based assays. The results of the study will help the FDA gain a better understanding of the pharmacology of human nicotinic receptor subtypes and provide screening platforms for efficient characterization of tobacco-related substances.

“This project will expand our repertoire of ligand-gated ion channel test systems in the therapeutically important neuronal nicotinic receptor family. We look forward to benefiting from FDA’s extensive background in this class of targets” said ChanTest Director of Pharmacology, Glenn Kirsch, Ph.D.

Dr. Arthur “Buzz” Brown, M.D., Ph.D., ChanTest Founder and CEO, added “ChanTest has unique expertise in ion channel cell line development and cell-based functional assays, as demonstrated by our track record in ion channel safety and discovery services serving the pharmaceutical industry. We view this project as a great opportunity to interact with scientists in the area of regulatory science.”

About ChanTest – The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 300 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in independent surveys since 2006. ChanTest is based in Cleveland, Ohio. For more information, e-mail info(at)chantest(dot)com.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
2. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. ChanTest Develops New Cardiotoxicity and Contractility Assay with Human Stem Cell Cardiomyocytes
5. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
8. Applied Genetics Initiates Commercial Operation
9. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
10. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
11. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: ... the company,s president and chief executive officer, will present at ... week in New York City . The ... December 1, 2015 at 9:30 a.m. EST. ... the website at least 15 minutes prior to the presentation ...
(Date:11/23/2015)... Calif., Nov. 23, 2015   Ceres, Inc . ... today financial results for the fiscal year ended August ... --> --> During ... forage and feed products with a better balance of ... signed distribution agreements with several leading crop input providers ...
(Date:11/23/2015)... PISCATAWAY, New Jersey , November 23, ... Centre (CCDC) announces the launch of the ... and the CSD-System, now complemented by three powerful ... support the discovery of new molecules, CSD-Materials for ... complete set of the CCDC,s applications incorporating CSD-Discovery ...
(Date:11/23/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... ), a biotechnology company focused on the discovery, ...
Breaking Biology Technology:
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific ... children, doctors and other healthcare providers face challenges in ... families and patients. In addition, as more children continue ... a patient,s adulthood and old age. John ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
Breaking Biology News(10 mins):